本帖最后由 老马 于 2012-1-13 21:20 编辑 ; d+ ~/ _6 m8 y3 V4 E
) {6 ?9 H- L1 o* c
爱必妥和阿瓦斯丁的比较
" E$ @1 w; \0 f
. o d8 ~% A9 `http://cancergrace.org/lung/2008/08/30/bms099-os-neg/( K0 K0 T/ H5 U H" d
( K+ T$ e# n% s$ d5 S+ U8 k
( Y, O* m- X" R/ a
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
+ ~7 z. i% m; U==================================================
" N( C/ F$ g" `Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)% s7 [" s+ t2 Y1 H
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
5 X- g6 F! K- AResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
) R2 _! \1 A9 z2 m8 G2 H. u% X0 n
|